Sarepta Therapeutics (SRPT +6.2%) trades notably higher in morning action.
Ultimately, the dystrophin production data for drisapersen (see here) was weak — only 12-29% of patients realized an increase in the precursor to dystrophin.
Baird maintains a Buy on SRPT. Price target is $63.
RBC is apparently out incrementally more positive on SRPT as well.